- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
New c-FIND test accurately diagnoses infection in minutes
1 July 2020
Institute researchers have developed a fast, new test for infections and infectious diseases that could transform Australia’s ability to provide targeted clinical care and respond to pandemics and biosecurity threats.
Called c-FIND, the test has the potential to rapidly and accurately detect multiple viral, bacterial or fungal infections within minutes – much faster than existing tests which can take days, or even weeks, to return a result.
and Associate Professor Marco Herold pictured
with a model of the c-FIND diagnostic device.
The test is now being developed into a portable, ‘point-of-care’ diagnostic device. Equipping clinicians with this device would enable them to diagnose infections without delay, and immediately provide the best care to high-risk patients, such as people with cancer.
The c-FIND program of research is being led by the Walter and Eliza Hall Institute of Medical Research, in collaboration with Melbourne Health, Murdoch Children’s Research Institute, Peter MacCallum Cancer Centre, The Royal Children’s Hospital, University of Melbourne, as well as industry partner and local biomedical technology company, Axxin Pty Ltd.
Transforming clinical care
Development is now underway to translate the c-FIND test into a portable, point-of-care device.
Following a successful bid for $1 million in funding from the Australian Government Medical Research Future Fund Frontiers program, the c-FIND research team is applying for funding that will include support for 13 clinical trials to rigorously assess implementation of the c-FIND diagnostic device in Australian healthcare settings with urgent, unmet diagnostic needs.
The trials aim to help advance Australia’s ability to rapidly and accurately diagnose:
- COVID-19 and other existing and emerging biosecurity threats
- high-risk cancer patients with asymptomatic or hard-to-detect infections
- infections in infants and children, and
- latent tuberculosis
Institute infectious disease physician and researcher Professor Marc Pellegrini said the c-FIND device could profoundly change how infections were detected and treated in a range of settings including hospitals, GP clinics, airports and ports of entry, and regional or remote centres.
“The introduction of a fast, reliable, user-friendly, point-of-care device to diagnose infections and infectious diseases on the spot, and even determine antimicrobial resistance, would be a game-changer for improving targeted patient care,” he said.
“c-FIND could prevent patients with hard-to-diagnose or hard-to-detect infections from waiting days, or weeks, for test results to come back whilst having expensive drug treatments, or unnecessary and invasive procedures.”
Pandemic preparedness
Professor Marc Pellegrini
Professor Pellegrini said the global COVID-19 pandemic had highlighted weaknesses in Australia’s ability to quickly detect, diagnose and respond to infectious disease threats.
“The current way that we test for COVID-19 is labour intensive, requiring highly trained staff, a central laboratory and expensive equipment to process samples. It can take days for patients to receive results, increasing the likelihood of disease transmission within the community,” Professor Pellegrini said.
“If a system such as c-FIND was available in the market, it could prevent disease spread and save lives by identifying infected people when they are tested so they can be isolated and treated without delay. It is widely accepted that pandemics will become more frequent in the future. A diagnostic device such as c-FIND would advance our capability to successfully respond to these emerging threats.”
Peter Mac infectious disease physician and associate director of health services research Professor Karin Thursky said the pandemic had knock-on effects for other parts of the healthcare system, such as cancer care, and significant impacts on vulnerable patients.
“With COVID-19 in the community, cancer patients are at significant risk and hospitals are having to put measures in place to protect them. This has meant that any cancer patient who presents with fever or respiratory symptoms is placed in strict isolation, and treated as COVID-19-positive until they return two negative results. These measures are distressing for patients and their loved ones, cause delays to cancer treatment being able to progress and place an additional burden on the healthcare system,” Professor Thursky said.
How does c-FIND work?
Institute CRISPR expert Associate Professor Marco Herold and his team have successfully adapted CRISPR for the development of the c-FIND test. The use of CRISPR technology in the diagnostics space has unleashed exciting potential to accurately detect genetic traces of disease-causing microbes within minutes.
“Once fully developed, the c-FIND diagnostic would involve taking a blood, mucus or saliva sample from a patient and – with minimal preparation – applying this to a small cartridge. This cartridge would then be run through the device to rapidly screen for as many as eight different viral, fungal or bacterial organisms at a time,” Associate Professor Herold said.
“c-FIND is fast as well as highly sensitive and specific. This means the technology has the ability to accurately identify if a person has certain infections, as well as rule out the infections a person does not have – it is unique for a test to excel in both these capabilities. Additionally, the system can be easily adapted to test for new and emerging infections,” he said.
Australian-led innovation
Institute director Professor Doug Hilton said c-FIND was a terrific example of Australian-led innovation and collaboration.
“c-FIND is the result of key collaborations between medical researchers, clinicians, hospitals and industry, leveraging their networks to produce a commercially-viable and competitive product that could deliver significant health and economic benefits to Australia and globally. It underscores Australian ingenuity and our self-sufficiency on the global stage,” Professor Hilton said.
“It is an incredibly exciting and potentially game-changing technology and I hope that further support can be secured so the team of talented researchers and clinicians can take this program of work to the next level and rigorously test the ability of c-FIND to improve Australian healthcare.”
About the Institute’s COVID-19 response
The Walter and Eliza Hall Institute is leading a number of major research responses to COVID-19 in collaboration with research partners in universities, hospitals and the private sector.
Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak, as well as in preparedness for future coronaviral disease outbreaks.
Media inquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
Answers to common questions about the c-FIND diagnostic device for testing infections and infectious diseases.
Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak as well as in preparedness for likely future coronaviral disease outbreaks.
Australia's first clinical trial to determine whether hydoroxychloroquine can prevent COVID-19 is open. The trial is recruiting frontline and allied healthcare workers from hospitals across the country.
The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.